AlphAIAlphAI — Financial news for AI agents
investing.comOCT 11 min read$HELP

Cybin rebrands to Helus Pharma, ticker symbol unchanged

Cybin Inc. has legally changed its name to Helus Pharma Inc. The rebrand, approved by shareholders, reflects the company's transition to a commercial-ready pharmaceutical firm. Shares will continue trading on Nasdaq and Cboe Canada under the ticker HELP. The company is developing serotonergic agonists for mental health disorders, with HLP003 in Phase 3 trials for major depressive disorder.

Original reporting
investing.com
Published Oct 1, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$HELP
Neutral
high confidence
Mentioned
$HELP
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HELPNeutralLow
01

Why it matters

The name change is a corporate‑action disclosure; no new clinical data or financing was announced.

02

Market read

The announcement is primarily informational for current shareholders and does not create a trading catalyst.

03

What to watch

The new CUSIP/ISIN may affect institutional processing but has no bearing on valuation.

Relevance 5/10Novelty 5/10Timing: effective immediately

Background

Helus Pharma (formerly Cybin) is a clinical‑stage biotech developing serotonergic agonists, with a Phase 3 candidate HLP003 that has FDA Breakthrough Therapy Designation.

Company-level read

Ticker impact

$HELPNeutralHigh confidence
Context

Cybin Inc. legally changed its name to Helus Pharma Inc. and will continue trading under the ticker HELP.

Expected impact

likely neutral as the market adjusts to the new branding without altering fundamentals.

Evidence & confidence

Name changes rarely move price unless accompanied by material events; no new financing or product news was disclosed.

Market effects

Sector

Limited; the rebrand does not affect the broader biotech or pharmaceutical sector.

Regional

None; the change is specific to the company and does not influence regional indices.

Global

Low; only relevant to investors holding HELP.

Counterpoint

What could challenge this read

If investors view the rebrand as a signal of strategic shift, they may anticipate future growth catalysts.

Key entities

  • company
    Helus Pharma Inc.

    Formerly Cybin Inc., now trading under HELP.

Read at source← All news

Related articles

SEP 18
$HELPMed

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Helus Pharma (HELP) shares rose to a 52-week high of $15.15 before falling 11% after Barclays initiated coverage with an Overweight rating and $35 price target. The company awaits Q4 trial results for its psychedelic drug HLP003, with FDA Breakthrough Therapy status. Analysts' average price target is $41.40, implying 195% upside. HELP has gained 53% year-to-date.

stocktwits.com2 min
AUG 14
$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

finanznachrichten.de6 min
JUL 21
$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min
JUL 17
$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min
JUN 25
$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min